Research Summary

ACIP Releases 2024 Adult Immunization Schedule

Jessica Ganga

In early 2024, the Advisory Committee on Immunization Practices (ACIP) released its 2024 immunization schedule for adults aged 19 years or older in the United States. The recommendation includes information on COVID-19, influenza, respiratory syncytial virus (RSV), polio vaccinations, and more.

The vaccination schedule breaks down the recommended vaccines by age group, medical condition, vaccine types (frequencies, intervals, considerations), and contraindications and precautions of each vaccine type.

“ACIP recommendations can be complex and challenging to implement. The purpose of the immunization schedule is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist health care providers in implementing current ACIP recommendations,” the authors wrote.

Notable changes to the Adult Immunization Schedule include:

  • The RSV vaccine has been added. Note, for pregnant persons, only PfizerBioNTech’s vaccine is recommended and should be given to those who are 32 through 36 weeks’ gestation.
  • For patients older than 60 years of age, any approved RSV vaccine can be administered. The decision to be vaccinated is based on shared decision-making between the patient and the physician.
  • All adults are recommended to receive at least one dose of the updated COVID-19 vaccine formula.
  • The mpox (monkeypox) is a new addition to the list. All adults in any age group who are at an increased risk of becoming infected should get a two-dose series of the vaccine.
  • For the polio vaccine, the recommendation now states that adults who are known or suspected to be unvaccinated or are incompletely vaccinated should complete a three-dose inactivated poliovirus vaccine (IPV) primary series. Further, any adults who are at an increased risk for exposure to polio that have completed their primary series may receive a one-time, lifetime IPV booster.
  • MenACWY-D, the meningococcal vaccine, was removed from the notes as it is no longer being distributed in the US. Information is provided on the use of the new pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp).

The 2024 schedule was also approved by the director of the CDC, the American College of Physicians, the American Academy of Family Physicians, the American College of Nurse-Midwives, the American Academy of Physician Associates, the American Pharmacists Association, and the Society for Healthcare Epidemiology of America.


 

Reference:
Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Recommended adult immunization schedule, United States, 2024. Ann Intern Med. Published online January 12, 2024. doi:10.7326/M23-3269